The impact of matching vaccine strains and post-sars public health efforts on reducing influenza-associated mortality among the elderly

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Chan, Ta Chien ^a,b   Hsiao, Chuhsing Kate ^a   Lee, Chang Chun ^a   Chiang, Po Huang ^b   Kao, Chuan Liang ^a,c   Liu, Chung Ming ^a   King, Chwan Chuen ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; INFLUENZA VIRUS HEMAGGLUTININ; VACCINE;

AGED; ANTIGENIC VARIATION; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; HOSPITAL INFECTION; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS A H3N2; MORTALITY; PNEUMONIA; PUBLIC HEALTH; RESPIRATORY TRACT DISEASE; RISK REDUCTION; SEASONAL VARIATION; SEVERE ACUTE RESPIRATORY SYNDROME; TREND STUDY; VIRUS ISOLATION; VIRUS STRAIN; WINTER;

AGED; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; POPULATION SURVEILLANCE; PUBLIC HEALTH PRACTICE; SEVERE ACUTE RESPIRATORY SYNDROME;

INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

EID: 77955335020     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011317     Document Type: Article

References (50)

1. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, et al. (2008) Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 57: 1-60.
2. Rivetti D, Jefferson T, Thomas R, Rudin M, Rivetti A, et al. (2006) Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 3: CD004876.
3. Rizzo C, Viboud C, Montomoli E, Simonsen L, Miller MA (2006) Influenzarelated mortality in the Italian elderly: no decline associated with increasing vaccination coverage. Vaccine 24: 6468-6475.
4. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, et al. (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. Jama 289: 179-186.
5. Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, et al. (2005) Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 165: 265-272.
6. Chew FT, Doraisingham S, Ling AE, Kumarasinghe G, Lee BW (1998) Seasonal trends of viral respiratory tract infections in the tropics. Epidemiol Infect 121: 121-128.
7. Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, et al. (2008) The global circulation of seasonal influenza A (H3N2) viruses. Science 320: 340-346.
8. Hsieh YC, Chen HY, Yen JJ, Liu DP, Chang LY, et al. (2005) Influenza in Taiwan: seasonality and vaccine strain match. J Microbiol Immunol Infect 38: 38-243.
9. World Health Organization. WHO Recommendations for Influenza Vaccine Composition.
10. Laboratory Virological Surveillance Report. Centers for Disease Control, Taiwan.
11. Casella G, Berger RL (2002) Statistical inference. Australia: Duxbury/Thomson Learning.
12. Pechirra P, Nunes B, Coelho A, Ribeiro C, Goncalves P, et al. (2005) Molecular characterization of the HA gene of influenza type B viruses. J Med Virol 77: 541-549.
13. Shih AC, Hsiao TC, Ho MS, Li WH (2007) Simultaneous amino acid substitutions at antigenic sites drive influenza A hemagglutinin evolution. Proc Natl Acad Sci U S A 104: 6283-6288.
14. Lon-di T (2008) Cabinet expands mini links with mainland. Taiwan Today.
15. Chen JM, Guo YJ, Wu KY, Guo JF, Wang M, et al. (2007) Exploration of the emergence of the Victoria lineage of influenza B virus. Arch Virol 152: 415-422.
16. Tsai HP, Wang HC, Kiang D, Huang SW, Kuo PH, et al. (2006) Increasing appearance of reassortant influenza B virus in Taiwan from 2002 to 2005. J Clin Microbiol 44: 2705-2713.
17. Taiwan CDC (2008) Process of standardized antiserum and antigen of human influenza viruses in Taiwan.
18. Donaldson LJ, Rutter PD, Ellis BM, Greaves FE, Mytton OT, et al. (2009) Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. Bmj 339: b5213.
19. Markel H, Lipman HB, Navarro JA, Sloan A, Michalsen JR, et al. (2007) Nonpharmaceutical interventions implemented by US cities during the 1918-1919 influenza pandemic. Jama 298: 644-654.
20. Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, et al. (2008) Global trendsin emerging infectious diseases. Nature 21: 990-993.
21. Wahl A, McCoy W, Schafer F, Bardet W, Buchli R, et al. (2009) T-cell tolerance for variability in an HLA class I-presented influenza A virus epitope. J Virol 83: 9206-9214.
22. Shih SR, Chen GW, Yang CC, Yang WZ, Liu DP, et al. (2005) Laboratorybased surveillance and molecular epidemiology of influenza virus in Taiwan. J Clin Microbiol 43: 1651-1661.
23. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, et al. (2004) Mapping the antigenic and genetic evolution of influenza virus. Science 305: 371-376.
24. Wang CS, Wang ST, Lai CT, Lin LJ, Chou P (2007) Impact of influenza vaccination on major cause-specific mortality. Vaccine 25: 1196-1203.
25. Jefferson TO, Rivetti D, Di Pietrantonj C, Rivetti A, Demicheli V (2007) Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. CD001269.
26. Goodwin K, Viboud C, Simonsen L (2006) Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24: 1159-1169.
27. Census Bureau US (2000) International Data Base (IDB).
28. Lu TH, Chou YJ, Liou CS (2007) Impact of SARS on healthcare utilization by disease categories: implications for delivery of healthcare services. Health Policy 83: 375-381.
29. Tang CS, Wong CY (2004) Factors influencing the wearing of facemasks to prevent the severe acute respiratory syndrome among adult Chinese in Hong Kong. Prev Med 39: 1187-1193.
30. Tan X, Li S, Wang C, Chen X, Wu X (2004) Severe acute respiratory syndrome epidemic and change of people's health behavior in China. Health Educ Res 19: 576-580.
31. Wong TW, Tam WW (2005) Handwashing practice and the use of personal protective equipment among medical students after the SARS epidemic in Hong Kong. Am J Infect Control 33: 580-586.
32. Yen MY, Wu TS, Chiu AW, Wong WW, Wang PE, et al. (2009) Taipei's use of a multi-channel mass risk communication program to rapidly reverse an epidemic of highly communicable disease. PLoS One 4: e7962.
33. Wu TS, Shih FY, Yen MY, Wu JS, Lu SW, et al. (2008) Establishing a nationwide emergency department-based syndromic surveillance system for better public health responses in Taiwan. BMC Public Health 8: 18.
34. Wung CH (2008) The reform of the hospital accreditation system in Taiwan. World Hosp Health Serv 44: 14-15, 18.
35. Shaw K (2006) The 2003 SARS outbreak and its impact on infection control practices. Public Health 120: 8-14.
36. Chu D, Chen RC, Ku CY, Chou P (2008) The impact of SARS on hospital performance. BMC Health Serv Res 8: 228.
37. Taiwan CDC (2010) Influenza Express in Taiwan - week 8, 2010. Taipei City.
38. Lau JT, Griffiths S, Choi KC, Tsui HY (2009) Widespread public misconception in the early phase of the H1N1 influenza epidemic. J Infect 59: 122-127.
39. Wikipedia (2009-2010) 2009 flu pandemic by country.
40. Rothberg MB, Haessler SD, Brown RB (2008) Complications of viral influenza. Am J Med 121: 258-264.
41. Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, et al. (2008) Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine 26 Suppl 4: D31-34.
42. Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, et al. (2008) Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine 26 Suppl 4: D31-34.
43. Boni MF (2008) Vaccination and antigenic drift in influenza. Vaccine 26 Suppl 3: C8-14.
44. Chen J, Deng YM (2009) Influenza virus antigenic variation, host antibody production and new approach to control epidemics. Virol J 6: 30.
45. Ndifon W, Dushoff J, Levin SA (2009) On the use of hemagglutinationinhibition for influenza surveillance: surveillance data are predictive of influenza vaccine effectiveness. Vaccine 27: 2447-2452.
46. Pan K, Deem MW (2009) Comment on Ndifon et al., "On the use of hemagglutination-inhibition for influenza surveillance: Surveillance data are predictive of influenza vaccine effectiveness". Vaccine 27: 5033-5034.
47. Rimmelzwaan GF, Kreijtz JH, Bodewes R, Fouchier RA, Osterhaus AD (2009) Influenza virus CTL epitopes, remarkably conserved and remarkably variable. Vaccine 27: 6363-6365.
48. Chambers TM, Quinlivan M, Sturgill T, Cullinane A, Horohov DW, et al. (2009) Influenza A viruses with truncated NS1 as modified live virus vaccines: pilot studies of safety and efficacy in horses. Equine Vet J 41: 87-92.
49. Steel J, Lowen AC, Pena L, Angel M, Solorzano A, et al. (2009) Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol 83: 1742-1753.
50. Hai R, Martinez-Sobrido L, Fraser KA, Ayllon J, Garcia-Sastre A, et al. (2008) Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J Virol 82: 10580-10590.